ADA Scientific Sessions 2026 Abstract

Survodutide: Differentiated GLP-1R and Glucagon Receptor (GCGR) Pharmacology Compared with Endogenous Ligands via Time-Resolved Assays

By Benedict Berger, Michael Schuler, Peter Haebel, Thomas Klein, Robert Augustin

Experiments in cellsInterventions

The paper

Benedict Berger, Michael Schuler, Peter Haebel, Thomas Klein, Robert Augustin

Biberach

ADA Scientific Sessions 2026 Abstract, 6 Jun 2026

Presented at ADA Scientific Sessions 2026, oral 1220-OR

doi.org/10.2337/db26-1220-or

The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
The New England Journal of Medicine4 Oct 2026
Retatrutide reduces weight and pain in adults with obesity
Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes